Efavirenz: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
k Bot: Perubahan kosmetika |
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.8 |
||
Baris 66:
== Indikasi ==
<span data-segmentid="265" class="cx-segment">Untuk infeksi HIV yang belum pernah diobati sebelumnya, [[Kementerian Kesehatan dan Layanan Masyarakat Amerika Serikat]] merekomendasikan penggunaan efavirenz dalam kombinasi dengan [[tenofovir/emtrisitabin]] (Truvada) sebagai piluhan utama pengobatan berbasis NNRTI pada pasien dewasa, remaja,<ref>{{Cite web|url=http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0/|title=Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents|date=July 14, 2016|archive-url=https://web.archive.org/web/20130523020606/http://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0|archive-date=May 23, 2013|dead-url=no}}</ref> dan anak-anak.<ref>{{Cite web|url=https://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guidelines/0/#|title=Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection|date=March 1, 2016|publisher=NIH AIDSinfo|archive-url=https://web.archive.org/web/20161115131825/https://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guidelines/0/|archive-date=November 15, 2016|dead-url=no}}</ref></span> [[Kementerian Kesehatan Republik Indonesia]] merekomendasikan kombinasi efavirenz, tenofovir, dan [[lamivudin]] (atau emtrisitabin) sebagai terapi HIV lini pertama.<ref name="kemenkes">{{cite web|url=http://siha.depkes.go.id/portal/files_upload/Buku_Permenkes_ARV_Cetak.pdf|title=Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2014 Tentang Pedoman Pengobatan Antiretroviral|accessdate=2019-06-26|archive-date=2019-10-05|archive-url=https://web.archive.org/web/20191005170803/http://siha.depkes.go.id/portal/files_upload/Buku_Permenkes_ARV_Cetak.pdf|dead-url=yes}}</ref>
<span data-segmentid="268" class="cx-segment">Efavirenz juga digunakan dalam bentuk kombinasi dengan [[Penanganan HIV/AIDS|antiretroviral]] lain untuk [[profilaksis pascapajanan]] agar mengurangi risiko infeksi HIV pada orang yang terpajan risiko penularan (misalnya tertusuk jarum suntik, behubungan seks tanpa perlindungan, dll</span><span data-segmentid="271" class="cx-segment">).<ref>{{Cite journal|last=Kuhar|first=David T.|last2=Henderson|first2=David K.|last3=Struble|first3=Kimberly A.|last4=Heneine|first4=Walid|last5=Thomas|first5=Vasavi|last6=Cheever|first6=Laura W.|last7=Gomaa|first7=Ahmed|last8=Panlilio|first8=Adelisa L.|date=2013-09-01|title=Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis|url=https://zenodo.org/record/1235708|journal=Infection Control & Hospital Epidemiology|volume=34|issue=9|pages=875–892|doi=10.1086/672271|issn=0899-823X|pmid=23917901}}</ref><ref>{{Cite web|url=https://www.cdc.gov/mmwr/PDF/rr/rr5402.pdf|title=Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States|last=|first=|date=|website=|publisher=Centers for Disease Control and Prevention|archive-url=https://web.archive.org/web/20170127161604/https://www.cdc.gov/mmwr/PDF/rr/rr5402.pdf|archive-date=January 27, 2017|dead-url=no|access-date=November 7, 2016}}</ref></span>
| |||